Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | TSHR | P16473 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5953079 | 0.77 | ANPEP (0.41) | — | |
| SCHEMBL474399 | 0.77 | — | — | |
| SCHEMBL9903702 | 0.76 | — | — | |
| SCHEMBL1300947 | 0.76 | — | — | |
| SCHEMBL661999 | 0.76 | ANPEP (0.34) | — | |
| SCHEMBL15228939 | 0.74 | — | — | |
| SCHEMBL17891917 | 0.74 | ANPEP (0.33) | ALDH1A1TSHRLMNA | |
| SCHEMBL18825922 | 0.73 | ALOX15 (0.36) | — | |
| Boric Acid SCHEMBL28714122 | 0.73 | ALDH1A1 (0.32) | ALDH1A1TSHRLMNA | |
| SCHEMBL3709629 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11267779-B2 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | PROMETIC PHARMA SMT LIMITED (GB) | 2022-03-08 | — | — | US | disclosed |
| US-11185521-B2 | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis | Liminal Biosciences Limited (GB) | 2021-11-30 | — | — | US | disclosed |
| CN-107106526-B | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration | 普罗米蒂克医药SMT有限公司 | 2021-05-28 | — | — | CN | disclosed |
| US-20210085626-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION | LIMINAL BIOSCIENCES LTD (GB) | 2021-03-25 | — | — | US | disclosed |
| US-20210002202-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses Thereof | PROMETIC BIOSCIENCES, INC. (CA) | 2021-01-07 | — | — | US | disclosed |
| US-10869849-B2 | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration | Liminal Biosciences Limited (GB) | 2020-12-22 | — | — | US | disclosed |
| EP-3443957-B1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | LIMINAL BIOSCIENCES LTD (GB) | 2020-11-25 | — | — | EP | disclosed |
| US-10815183-B2 | Substituted aromatic compounds and pharmaceutical uses thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2020-10-27 | — | — | US | disclosed |
| US-20200237693-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | LIMINAL BIOSCIENCES INC (GB) | 2020-07-30 | — | — | US | disclosed |
| CN-106999456-B | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis | 里米诺生物科学有限公司 | 2020-07-10 | — | — | CN | disclosed |
| US-9114118-B2 | Compounds and compositions for the treatment of cancer | PROMETIC BIOSCIENCES INC. (CA) | 2015-08-25 | — | — | US | disclosed |
| US-20150094372-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | Liminal Biosciences Limited (GB) | 2015-04-02 | — | — | US | disclosed |
| US-8927765-B2 | Substituted aromatic compounds and pharmaceutical uses thereof | PROMETIC BIOSCIENCES INC. (CA) | 2015-01-06 | — | — | US | disclosed |
| WO-2014138907-A1 | SUBSTITUTED AROMATIC COMPOUNDS FOR THE TREATMENT OF PULMONARY FIBROSIS, LIVER FIBROSIS, SKIN FIBROSIS AND CARDIAC FIBROSIS | PROMETIC BIOSCIENCES INC. (CA) | 2014-09-18 | — | — | WO | disclosed |
| EP-2632452-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | ProMetic BioSciences Inc. (CA) | 2013-09-04 | — | — | EP | disclosed |
| US-20130217645-A1 | Compounds and Compositions for the Treatment of Cancer | PROMETIC BIOSCIENCES INC. (CA) | 2013-08-22 | — | — | US | disclosed |
| WO-2012097427-A1 | COMPOUNDS AND COMPOSITIONS FOR THE TREATMENT OF CANCER | PROMETIC BIOSCIENCES INC. (CA) | 2012-07-26 | — | — | WO | disclosed |
| US-20120088784-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses thereof | PROMETIC PHARMA SMT LIMITED (GB) | 2012-04-12 | — | — | US | disclosed |
| EP-2427416-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | ProMetic BioSciences Inc. (CA) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010127440-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | PROMETIC BIOSCIENCES INC. (CA) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210085626-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR TISSUE SELF-REPAIR AND REGENERATION | COL1A1, CCNH, COL2A1 | ALDH1A1 129/4885TSHR 2754/4885LMNA 1277/4885 |
| US-20130217645-A1 | Compounds and Compositions for the Treatment of Cancer | DCK, TOP2B, TOP2A | ALDH1A1 467/4885TSHR 4345/4885LMNA 3785/4885 |
| US-20200237693-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL COMPOSITIONS FOR THE PREVENTION AND TREATMENT OF OSTEOPOROSIS | ADIPOR1, ADIPOR2, FN1 | ALDH1A1 1129/4885TSHR 534/4885LMNA 1541/4885 |
| US-10815183-B2 | Substituted aromatic compounds and pharmaceutical uses thereof | TYR, PAH, REN | ALDH1A1 190/4885TSHR 4202/4885LMNA 2244/4885 |
| US-20210002202-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses Thereof | TYR, PAH, REN | ALDH1A1 190/4885TSHR 4202/4885LMNA 2244/4885 |
| US-10869849-B2 | Substituted aromatic compounds and pharmaceutical compositions for tissue self-repair and regeneration | COL1A1, CCNH, COL2A1 | ALDH1A1 129/4885TSHR 2754/4885LMNA 1277/4885 |
| US-20150094372-A1 | SUBSTITUTED AROMATIC COMPOUNDS AND PHARMACEUTICAL USES THEREOF | TYR, PAH, REN | ALDH1A1 190/4885TSHR 4202/4885LMNA 2244/4885 |
| US-11185521-B2 | Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of osteoporosis | ADIPOR1, ADIPOR2, FN1 | ALDH1A1 1129/4885TSHR 534/4885LMNA 1541/4885 |
| US-20120088784-A1 | Substituted Aromatic Compounds and Pharmaceutical Uses thereof | TYR, PAH, REN | ALDH1A1 190/4885TSHR 4202/4885LMNA 2244/4885 |
| US-11267779-B2 | Substituted aromatic compounds for the treatment of pulmonary fibrosis, liver fibrosis, skin fibrosis and cardiac fibrosis | PAH, HRH3, CFH | ALDH1A1 402/4885TSHR 2743/4885LMNA 1678/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.